Review Backs ApoB to Flag Residual Risk That LDL-C Can Miss

Apolipoprotein B (ApoB) may capture residual atherosclerotic cardiovascular disease (ASCVD) risk that standard cholesterol measures miss, particularly in patients with elevated triglycerides, metabolic abnormalities, or discordant lipid values, according to a review published in Frontiers in Cardiovascular Medicine.¹

Because each atherogenic lipoprotein particle carries a single ApoB molecule, plasma ApoB offers a direct count of circulating atherogenic particles regardless of how much cholesterol each one holds. LDL cholesterol (LDL-C), by contrast, reflects only cholesterol mass, and LDL-C calculated with the Friedewald equation shows substantial errors once triglycerides exceed 4.5 mmol/L. ApoB results are also unaffected by fasting status and require no additional calculation.

Discordant ApoB and LDL-C Values Signal Hidden Risk

In a Copenhagen cohort of 13,015 statin-treated patients cited in the review, ApoB was a more accurate marker of all-cause mortality risk than LDL-C or nonHDL cholesterol (nonHDL-C) and a more accurate marker of myocardial infarction risk than LDL-C. In a cohort of 36,460 Chinese patients with coronary artery disease, baseline ApoB was linearly associated with long-term all-cause mortality and showed greater prognostic value than LDL-C.

Much of ApoB's added value appears when the 2 markers disagree. Among young adults in a multicenter prospective cohort, those with low LDL-C but high ApoB had a significantly increased risk of coronary artery calcification (OR, approximately 1.55-2.28). In the Women's Health Study, ApoB and LDL-C were highly correlated (correlation coefficient, 0.785), yet approximately 18.9% of participants showed discordance, a group in whom LDL-C alone could underestimate or overestimate coronary heart disease risk.

The authors cautioned that Mendelian randomization analyses identifying ApoB as a leading lipid determinant of coronary artery disease cannot fully separate the effect of the ApoB molecule itself from that of the number of ApoB-containing particles.

Guidelines Position ApoB as a Complement to LDL-C

The 2019 European Society of Cardiology/European Atherosclerosis Society guidelines named ApoB a secondary treatment target, with recommended levels below 65 mg/dL, 80 mg/dL, and 100 mg/dL for patients at very high, high, and moderate cardiovascular risk, respectively. The 2026 American College of Cardiology/American Heart Association (ACC/AHA) multisociety guideline continues to recommend LDL-C and nonHDL-C as the primary treatment targets, with ApoB used mainly for additional risk assessment in selected patients.

Under that guideline, ApoB may be measured to assess residual ASCVD risk and guide treatment in people with cardiovascular-kidney-metabolic syndrome, type 2 diabetes, high triglycerides, or known cardiovascular disease who have reached their LDL-C and nonHDL-C goals.²

Because ApoB requires an additional laboratory test and tracks closely with LDL-C in most patients, the review authors suggested using it selectively in patients with elevated triglycerides, metabolic abnormalities, or ApoB–LDL-C discordance rather than replacing LDL-C entirely.¹

No Outcome Trials Have Yet Targeted ApoB Directly

Several available therapies lower ApoB, including evolocumab, inclisiran, and bempedoic acid added to maximally tolerated statin therapy. Zodasiran, an RNA interference therapy targeting angiopoietin-like protein 3, reduced ApoB in phase 2 studies and remains in development.

However, no randomized controlled trials have used ApoB as the primary treatment target with cardiovascular events as the primary outcome, so current ApoB targets rest mainly on observational studies and analyses of lipid-lowering trials. Assay differences also persist: a comparison of 3 ApoB assays in the Multi-Ethnic Study of Atherosclerosis found that inter-method differences could affect risk classification in some individuals. Reference ranges may vary by ethnicity and region, and evidence remains limited in children and older adults.

“Future studies should further evaluate ApoB-guided treatment strategies through prospective clinical trials, establish population-specific reference ranges and treatment targets, and improve the standardization and accessibility of ApoB measurement,” wrote the researchers of the study. “With continued accumulation of evidence, ApoB may serve as an important component of personalized cardiovascular risk assessment and lipid management.”

References

1. Li L, Feng Y, Li X, et al. Apolipoprotein B in cardiovascular risk assessment: beyond traditional lipid markers. Front Cardiovasc Med. 2026;13:1857230. doi:10.3389/fcvm.2026.1857230 https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2026.1857230/full
2. ACC/American Heart Association issue updated guideline for managing lipids, cholesterol. News release. American Heart Association. March 13, 2026. Accessed October 15, 2026. https://newsroom.heart.org/news/accaha-issue-updated-guideline-for-managing-lipids-cholesterol